Ivermectin (Systemic)

Brand names: Stromectol
Drug class: Antineoplastic Agents

Usage of Ivermectin (Systemic)

Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

Ascariasis

Treatment of ascariasis† [off-label] caused by Ascaris lumbricoides. Albendazole and mebendazole are drugs of choice. Ivermectin also recommended as a drug of choice, but efficacy not clearly established.

Filariasis

Treatment of onchocerciasis (filariasis caused by Onchocerca volvulus; commonly referred to as river blindness). Drug of choice. Used in individual patients and in mass treatment and control programs. Does not kill adult O. volvulus worms, but decreases microfilarial load in skin for approximately 6–12 months following a single dose.

Treatment of filariasis caused by Mansonella streptocerca† [off-label]. Diethylcarbamazine (available in US from CDC) and ivermectin are drugs of choice. Diethylcarbamazine is potentially curative since it is active against both adult worms and microfilariae; ivermectin is effective only against microfilariae.

Has been used for treatment of filariasis caused by M. ozzardi† [off-label].

Treatment of filariasis caused by Wuchereria bancrofti† [off-label] or Brugia malayi† [off-label]; used alone or in conjunction with albendazole or diethylcarbamazine (available in US from CDC). Ivermectin does not kill adult worms, but may play an important role in mass treatment programs to suppress microfilaremia and thereby interrupt transmission in endemic areas. Diethylcarbamazine is usual drug of choice, especially for individual patients when the goal is to kill the adult worm.

Has been used in conjunction with albendazole to treat co-infection with W. bancrofti† and O. volvulus.

Has been used to reduce microfilaremia in the treatment of loiasis caused by Loa loa†. Generally not recommended since rapid killing of microfilariae increases risk of encephalopathy. (See Encephalopathy Risk in Onchocerciasis and Loiasis under Cautions.) Drug of choice for loiasis is diethylcarbamazine (available in US from CDC); preferred alternative is albendazole since it has a slower onset of action and decreased risk of encephalopathy compared with ivermectin.

Gnathostomiasis

Treatment of gnathostomiasis† caused by Gnathostoma spinigerum. Drug of choice (with or without surgical removal) is albendazole or ivermectin.

Hookworm Infections

Treatment of cutaneous larva migrans† (creeping eruption) caused by Ancylostoma braziliense (dog and cat hookworm) or Ancylostoma caninum (dog hookworm). Usually self-limited with spontaneous cure after several weeks or months; when treatment is indicated, drug of choice is albendazole or ivermectin.

Do not use for treatment of intestinal hookworm infections caused by Ancylostoma duodenale or Necator americanus. Appears to have little or no activity against these hookworms. Albendazole, mebendazole, and pyrantel pamoate are drugs of choice.

Strongyloidiasis

Treatment of intestinal (i.e., nondisseminated) strongyloidiasis caused by Strongyloides stercoralis. Drug of choice; alternative is albendazole.

Has been used for treatment of strongyloidiasis hyperinfection with disseminated disease† and for treatment of strongyloidiasis in immunocompromised patients. Drug of choice; alternative is albendazole. Repeated or prolonged ivermectin therapy or use with other drugs may be necessary; treatment failures reported.

Empiric treatment of strongyloidiasis before transplantation to prevent hyperinfection in hematopoietic stem cell transplant (HSCT) recipients†. Such treatment recommended by CDC, IDSA, ASBMT, and others for HSCT candidates with positive strongyloidiasis screening tests or possible exposure (e.g., unexplained eosinophilia and travel or residence history suggestive of S. stercoralis exposure [even if seronegative or stool-negative]). Data insufficient to recommend prophylaxis after HSCT to prevent recurrence of strongyloidiasis in such patients.

Trichuriasis

Treatment of trichuriasis† caused by Trichuris trichiura (whipworm). Albendazole is drug of choice; alternatives are mebendazole and ivermectin.

Pediculosis

Treatment of pediculosis capitis† (head lice infestation). AAP and others usually recommend topical treatment with OTC preparation of permethrin 1% or pyrethrins with piperonyl butoxide for initial treatment; other topical pediculicides (e.g., malathion 0.5%, Benzyl Alcohol 5%, spinosad 0.9%) recommended if OTC preparations ineffective or permethrin or pyrethrin resistance suspected. Oral ivermectin recommended as an alternative for infestations not responding to or resistant to topical agents.

Alternative for treatment of pediculosis pubis† (pubic lice infestation). Drug of choice is topical permethrin 1% or topical pyrethrins with piperonyl butoxide.

Alternative for treatment of pediculosis corporis† (body lice infestation). In some cases, body louse infestations may be treated by improved hygiene and by decontaminating clothes and bedding by washing at temperatures that kill lice. If infestation severe and a pediculicide necessary, use agents recommended for pediculosis capitis (i.e., topical permethrin or topical pyrethrins with piperonyl butoxide or, alternatively, other topical pediculicides or oral ivermectin).

Scabies

Treatment of scabies† (mite infestation). CDC, AAP, and others usually recommend topical permethrin 5% as scabicide of choice; CDC also recommends oral ivermectin as a drug of choice.

May be particularly useful in refractory scabies infestations, for control of outbreaks in institutions, and when compliance with topical therapy is difficult.

Has been used for treatment of severe or crusted (i.e., Norwegian) scabies†. May be a drug of choice in immunocompromised patients. Aggressive treatment (multiple-dose oral ivermectin regimen with concomitant topical scabicide) usually necessary.

Relate drugs

How to use Ivermectin (Systemic)

General

Onchocerciasis

  • Does not kill adult O. volvulus worms, but may decrease microfilarial load in skin for approximately 6–12 months following a single dose. Follow-up and retreatment required since adult female worms continue to produce microfilaria for 9–15 years.
  • Recommendations for retreatment intervals vary. For individual patients, retreatment once every 6–12 months until asymptomatic has been recommended; intervals as short as 3 months can be considered. When used in mass treatment and control programs (community-wide mass drug administration [MDA] programs), retreatment often given at 6- or 12-month intervals; some programs use 3-month intervals to suppress microfilarial counts to a level where transmission can be interrupted.
  • Adjunctive surgical excision of suBCutaneous nodules may help eliminate microfilariae-producing adult worms, but there is no evidence that nodulectomies reduce blindness associated with onchocerciasis.

    • Strongyloidiasis

  • After treatment, perform follow-up stool examinations to verify eradication of S. stercoralis; retreatment indicated if recrudescence of larvae observed.
  • Optimal dosage for treatment of intestinal strongyloidiasis in immunocompromised (e.g., HIV-infected) patients not established. Several courses of therapy (i.e., at intervals of 2 weeks) may be necessary; cure may not be achieved. Control of extra-intestinal strongyloidiasis in such patients is difficult; once-monthly suppressive treatment may be helpful.

    • Pediculosis†

  • To avoid reinfestation or transmission of lice, most experts recommend that clothing, hats, bed linen, and towels worn or used by infested individual during the 2 days prior to treatment be decontaminated (machine-washed in hot water and dried in a hot dryer).
  • Items that cannot be laundered can be dry-cleaned or sealed in a plastic bag for 2 weeks.
  • Decontaminate combs, brushes, and hair clips used by infested individual by soaking in hot water (>54°C) for 5–10 minutes.
  • Thoroughly vacuum car seats, upholstered furniture, and floors of rooms inhabited by infested individual. Fumigation of living areas not necessary.
  • Evaluate other family members and close contacts of infested individual and treat if lice infestation present. Some clinicians suggest treating family members who share a bed with infested individual, even if no live lice found on this family member. Ideally, treat all infested household members and close contacts at same time.
  • A fine-toothed or nit comb may be used to remove any remaining nits (eggs) or nit shells from hair. Some clinicians do not consider nit removal necessary since only live lice can be transmitted, but recommend it for aesthetic reasons and to decrease diagnostic confusion and unnecessary retreatment. Other clinicians recommend removal of nits (especially those within 1 cm of scalp) to decrease risk of reinfestation since no pediculicide is 100% ovicidal and potentially viable nits may remain on hair after treatment. Although many schools will not allow children with nits to attend, AAP and other experts consider these no-nit policies excessive.

    • Scabies†

  • Consider treating family members of patients with scabies since asymptomatic scabies is common.
  • Skin eruptions at scabies infestation sites may worsen (increased lesion count and inflammation) during first few days after initiation of treatment.
  • Pruritus may persist 2–4 weeks after treatment while dead mites in the outer skin layers slough off with normal exfoliation.
  • HIV-infected patients with uncomplicated scabies should receive same treatment as those without HIV infection.
  • If used for treatment of crusted scabies†, multiple-dose regimen in conjunction with a topical scabicide recommended to reduce risk of treatment failure. Immunocompromised patients, including those with HIV infection, are at increased risk of developing crusted scabies; manage such patients in consultation with an expert.

    • Administration

    Oral Administration

    Administer orally. Take tablets on an empty stomach with water.

    Dosage

    Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

    Pediatric Patients

    Safety and efficacy not established in children weighing <15 kg.

    Ascariasis† Ascaris lumbricoides infections† Oral

    Children weighing ≥15 kg: 150–200 mcg/kg as a single dose.

    Filariasis Onchocerciasis (Filariasis Caused by Onchocerca volvulus) Oral

    Children weighing ≥15 kg: Approximately 150 mcg/kg as a single dose.

    For individual patients, retreat once every 6–12 months until asymptomatic; can consider intervals as short as 3 months.

    In international mass treatment and control programs (MDA programs), typically administered at 6- or 12-month intervals. Some (e.g., in hyperendemic areas) use 3-month intervals.

    Approximate Ivermectin Dose for Treatment of Onchocerciasis (Based on Patient Weight) 1

    Patient Weight (kg)

    Single Oral Dose

    15–25

    3 mg

    26–44

    6 mg

    45–64

    9 mg

    65–84

    12 mg

    ≥85

    150 mcg/kg

    Alternatively, in MDA programs, dosage is estimated based on height† since weighing recipients may be impractical (e.g., in rural areas of developing countries).

    Approximate Ivermectin Dose for Treatment of Onchocerciasis in Mass Treatment Programs (Based on Patient Height†)8889118

    Patient Height (cm)

    Single Oral Dose

    90–119

    3 mg

    120–140

    6 mg

    141–158

    9 mg

    ≥159

    12 mg

    Mansonella streptocerca Infections† Oral

    Children weighing ≥15 kg: 150 mcg/kg as a single dose.

    Wuchereria bancrofti Infections† Oral

    150–400 mcg/kg as a single dose has been used; often used in conjunction with a single dose of albendazole or diethylcarbamazine (available in US from CDC).

    Gnathostomiasis† Gnathostoma spinigerum Infections† Oral

    Children weighing ≥15 kg: 200 mcg/kg once daily for 2 days.

    Hookworm Infections† Cutaneous Larva Migrans (Creeping Eruption Caused by Dog and Cat Hookworms)† Oral

    Children weighing ≥15 kg: 200 mcg/kg once daily for 1–2 days.

    Strongyloidiasis Treatment of Intestinal Strongyloides stercoralis Infections Oral

    Children weighing ≥15 kg: Approximately 200 mcg/kg as a single dose. Alternatively, some clinicians recommend 200 mcg/kg once daily for 2 days.

    Manufacturer states additional doses not generally necessary, but follow-up stool examinations required to verify eradication. Retreat if recrudescence of larvae observed.

    Approximate Ivermectin Dose for Treatment of Intestinal Strongyloidiasis (Based on Patient Weight)1

    Patient Weight (kg)

    Single Oral Dose

    15–24

    3 mg

    25–35

    6 mg

    36–50

    9 mg

    51–65

    12 mg

    66–79

    15 mg

    ≥80

    200 mcg/kg

    Prevention of Strongyloides Hyperinfection in HSCT Candidates at Risk† Oral

    Children weighing ≥15 kg: 200 mcg/kg once daily for 2 days; repeat after 2 weeks. Complete regimen prior to HSCT.

    In immunocompromised candidates, multiple courses at 2-week intervals may be required and cure may not be achievable.

    Trichuriasis† Trichuris trichiura Infections† Oral

    Children weighing ≥15 kg: 200 mcg/kg once daily for 3 days.

    Pediculosis† Pediculosis Capitis (Head Lice Infestation)† Oral

    Children weighing ≥15 kg: 200 or 400 mcg/kg . Although >1 dose usually necessary, optimal number of doses and dosing interval not established.

    A 2-dose regimen of 200- or 400-mcg/kg doses given 7–10 days apart has been used.

    Pediculosis Pubis (Pubic Lice Infestation)† Oral

    A 2-dose regimen of 250-mcg/kg doses given 2 weeks apart recommended by CDC.

    Scabies† Oral

    Children weighing ≥15 kg: A 2-dose regimen of 200-mcg/kg doses given 2 weeks apart recommended by CDC.

    Others recommend 2-dose regimen of 200-mcg/kg doses given ≥7 days apart.

    Optimal number of doses not determined; 2 doses usually recommended, especially in immunocompromised patients.

    Crusted (Norwegian) Scabies† Oral

    Children weighing ≥15 kg: Multiple-dose regimen consisting of 200-mcg/kg doses. CDC and others recommend doses be given once daily on days 1, 2, 8, 9, and 15; severe cases may also require doses on days 22 and 29.

    Usually used in conjunction with a topical scabicide (e.g., topical Benzyl benzoate 5%, topical permethrin 5%).

    Adults

    Ascariasis† Ascaris lumbricoides Infections† Oral

    150–200 mcg/kg as a single dose.

    Filariasis Onchocerciasis (Filariasis Caused by Onchocerca volvulus) Oral

    Approximately 150 mcg/kg as a single dose.

    For individual patients, retreat once every 6–12 months until asymptomatic; can consider intervals as short as 3 months.

    Approximate Ivermectin Dose for Treatment of Onchocerciasis (Based on Patient Weight)1

    Patient Weight (kg)

    Single Oral Dose

    15–25

    3 mg

    26–44

    6 mg

    45–64

    9 mg

    65–84

    12 mg

    ≥85

    150 mcg/kg

    Alternatively, in some mass treatment and control programs, dosage is estimated based on height†; weighing recipients may be impractical (e.g., in rural areas of developing countries).

    Approximate Ivermectin Dose for Treatment of Onchocerciasis in Mass Treatment Programs (Based on Patient Height†) 8889

    Patient Height (cm)

    Single Oral Dose

    90–119

    3 mg

    120–140

    6 mg

    141–158

    9 mg

    ≥159

    12 mg

    Mansonella Infections† Oral

    Filariasis caused by M. streptocerca†: 150 mcg/kg as a single dose.

    Filariasis caused by M. ozzardi†: 200 mcg/kg as a single dose has been used.

    Wuchereria bancrofti Infections† Oral

    150–400 mcg/kg as a single dose has been used; often used in conjunction with a single dose of albendazole or diethylcarbamazine (available in US from CDC).

    Gnathostomiasis† Gnathostoma spinigerum Infections† Oral

    200 mcg/kg once daily for 2 days.

    Hookworm Infections† Cutaneous Larva Migrans (Creeping Eruption Caused by Dog and Cat Hookworms)† Oral

    200 mcg/kg once daily for 1–2 days.

    Strongyloidiasis Treatment of Intestinal Strongyloides stercoralis Infections Oral

    Approximately 200 mcg/kg as a single dose. Alternatively, some clinicians recommend 200 mcg/kg once daily for 2 days.

    Manufacturer states additional doses not generally necessary, but follow-up stool examinations required to verify eradication. Retreat if recrudescence of larvae observed.

    Approximate Single Dose for Treatment of Intestinal Strongyloidiasis (Based on Patient Weight)1

    Patient Weight (kg)

    Single Oral Dose

    15–24

    3 mg

    25–35

    6 mg

    36–50

    9 mg

    51–65

    12 mg

    66–79

    15 mg

    ≥80

    200 mcg/kg

    Prevention of Strongyloides Hyperinfection in HSCT Candidates at Risk† Oral

    200 mcg/kg once daily for 2 days; repeat after 2 weeks. Complete regimen prior to HSCT.

    In immunocompromised candidates, multiple courses at 2-week intervals may be required and cure may not be achievable.

    Trichuriasis† Trichuris trichiura Infections† Oral

    200 mcg/kg once daily for 3 days.

    Pediculosis† Pediculosis Capitis (Head Lice Infestation)† Oral

    200 or 400 mcg/kg. Although >1 dose usually necessary, optimal number of doses and dosing interval not established.

    A 2-dose regimen of 200- or 400-mcg/kg doses given 7–10 days apart has been used.

    Pediculosis Pubis (Pubic Lice Infestation)† Oral

    A 2-dose regimen of 250-mcg/kg doses given 2 weeks apart recommended by CDC.

    Scabies† Oral

    A 2-dose regimen of 200-mcg/kg doses given 2 weeks apart recommended by CDC.

    Others recommend 2-dose regimen of 200-mcg/kg doses given ≥7 days apart.

    Optimal number of doses not determined; 2 doses usually recommended, especially in immunocompromised patients.

    Crusted (Norwegian) Scabies† Oral

    Multiple-dose regimen consisting of 200-mcg/kg doses. CDC and others recommend doses be given once daily on days 1, 2, 8, 9, and 15; severe cases may also require doses on days 22 and 29.

    Use in conjunction with a topical scabicide (e.g., topical benzyl benzoate 5%, topical permethrin 5%).

    Warnings

    Contraindications

    Pending revision, the material in this section should be considered in light of more recently available information in the MedWatch notification at the beginning of this monograph.

  • Hypersensitivity to ivermectin or any ingredient in the formulation.

    • Warnings/Precautions

    Warnings

    Mazzotti Reactions

    Cutaneous and/or systemic reactions of varying severity (Mazzotti reactions) may occur in patients with onchocerciasis receiving microfilaricidal drugs (e.g., diethylcarbamazine, ivermectin). These may be secondary to allergic and inflammatory responses to death of microfilariae.

    Mazzotti reactions may include pruritus, edema, frank urticarial rash (papular and pustular), fever, arthralgia/synovitis, and lymph node enlargement/tenderness (e.g., axillary, cervical, inguinal).

    Mazzotti-type reactions appear to be less severe and occur less frequently with ivermectin than with diethylcarbamazine.

    These reactions may be most severe in previously untreated patients and may diminish with subsequent treatment (e.g., annual mass treatment and control programs).

    Optimal treatment of severe Mazzotti reactions not determined. Oral or IV hydration, recumbency, and/or parenteral corticosteroids have been used to treat postural hypotension; for supportive treatment of mild to moderate reactions, antihistamines, corticosteroids, and/or aspirin have been used.

    Mazzotti-type reactions observed with treatment of onchocerciasis or the disease itself would not be anticipated in patients being treated for strongyloidiasis.

    Ocular Effects

    Ocular reactions (e.g., abnormal sensation in the eyes, eyelid edema, anterior uveitis, conjunctivitis, limbitis, keratitis, chorioretinitis or choroiditis) may occur in patients being treated for onchocerciasis or may occur secondary to the disease itself.

    Ocular reactions observed with treatment of onchocerciasis or the disease itself would not be anticipated in patients being treated for strongyloidiasis.

    Neurotoxicity

    Not recommended in patients with an impaired blood-brain barrier (e.g., meningitis, African trypanosomiasis) or CNS disorders that may increase CNS penetration of the drug; potential interaction with CNS GABA receptors. (See Interactions.)

    P-glycoprotein, encoded by the multi-drug resistance gene (MDR1), functions as a drug efflux transporter; appears to limit CNS uptake and prevent potentially fatal neurotoxicity.

    Theoretical increased risk of neurotoxicity in patients with altered expression or function of P-glycoprotein (e.g. through genetic polymorphism, concomitant use of inhibitors of the P-glycoprotein transport system); if such increased susceptibility exists, apparently rare. (See Interactions.)

    Although not reported in humans to date, neurotoxicity (e.g., tremors, ataxia, sweating, lethargy, coma, death) has occurred in certain animals with extreme sensitivity (e.g., collie dogs, inbred strains of mice); increased CNS sensitivity appears to be secondary to absent or dysfunctional MDR and P-glycoprotein.

    General Precautions

    Encephalopathy Risk in Onchocerciasis and Loiasis

    Consider possible severe adverse effects when treating onchocerciasis in patients from areas where onchocerciasis and loiasis are co-endemic.

    Patients with onchocerciasis who also are heavily infected with L. loa may develop serious or fatal neurologic events (e.g., encephalopathy, coma) either spontaneously or following rapid killing of microfilariae with effective microfilaricidal agents, including ivermectin.

    Back pain, conjunctival hemorrhage, dyspnea, urinary and/or fecal incontinence, difficulty standing or walking, mental status changes, confusion, lethargy, stupor, seizures, coma, dysarthria or aphasia, fever, headache, or chills also reported.

    Reported rarely in patients receiving ivermectin, but a definite causal relationship not established.

    Pretreatment assessment for loiasis and careful post-treatment follow-up recommended when treatment is planned for any reason in patients with significant exposure to L. loa in endemic areas (West or Central Africa).

    Other Precautions in Filariasis

    Increased risk of severe adverse reactions (e.g., edema, aggravation of onchodermatitis) in patients with hyperreactive onchodermatitis (sowdah).

    Does not kill adult O. volvulus worms, but decreases microfilarial load in skin for approximately 6–12 months following a single dose. Follow-up and retreatment required since the adult female worms continue to produce microfilaria for 9–15 years.

    Specific Populations

    Pregnancy

    Category C.

    Has been inadvertently given to pregnant women during mass distribution campaigns for treatment and control of onchocerciasis or lymphatic filariasis, but was not associated with adverse pregnancy outcomes, congenital malformations, or differences in developmental status or disease patterns in the offspring of such women.

    World Health Organization (WHO) and other experts state that use for treatment of onchocerciasis after the first trimester probably is acceptable based on the high risk of infection-associated blindness if untreated.

    Lactation

    Distributed into milk. Use in nursing women only when risk of delayed treatment in the woman outweighs risks to the nursing infant.

    Pediatric Use

    Safety and efficacy not established in children weighing <15 kg.

    Some clinicians state that use not recommended in young children (e.g., those weighing <15 kg or <2 years of age) partly because the blood-brain barrier may be less developed than in older patients. (See Neurotoxicity under Cautions.)

    Limited data suggest that safety in those 6–13 years of age similar to that in adults.

    Geriatric Use

    Insufficient experience in controlled clinical studies in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults. Other clinical experience has not revealed age-related differences in response.

    Use with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.

    Common Adverse Effects

    Treatment of onchocerciasis: Worsening of Mazzotti reactions (see Mazzotti Reactions under Cautions), ocular effects, peripheral edema, tachycardia, eosinophilia.

    Treatment of strongyloidiasis: GI effects (diarrhea, nausea, anorexia, constipation, vomiting, abdominal pain, abdominal distention), decreased leukocyte count, eosinophilia, increased hemoglobin, increased serum ALT or AST, nervous system effects (dizziness, asthenia or fatigue, somnolence, tremor, vertigo), pruritus, rash, urticaria.

    What other drugs will affect Ivermectin (Systemic)

    Appears to be metabolized principally by CYP3A4 and, to lesser extent, by 2D6 and 2E1. Does not inhibit CYP3A4, 2D6, 2C9, 1A2, and 2E1.

    Drugs with GABA-potentiating Activity

    Concomitant use with drugs with GABA-potentiating activity (e.g., barbiturates, benzodiazepines, sodium oxybate, valproic acid) not recommended. Ivermectin may interact with GABA receptors in the CNS.

    Drugs Affecting or Affected by P-glycoprotein Transport

    Appears to be a substrate of P-glycoprotein transport system. Theoretical possibility of interactions with inducers (e.g., amprenavir, clotrimazole, phenothiazines, rifampin, ritonavir, St. John’s wort) or inhibitors (e.g., amiodarone, carvedilol, clarithromycin, cyclosporine, erythromycin, itraconazole, ketoconazole, quinidine, ritonavir, tamoxifen, verapamil) of this system. Concomitant use with inhibitors theoretically could result in increased brain concentrations of ivermectin and neurotoxicity

    Specific Drugs

    Drug

    Interaction

    Comments

    Alcohol

    Increased plasma ivermectin concentrations

    Clinical importance unknown

    Anticoagulants

    Postmarketing reports of elevated INR when used concomitantly with warfarin

    Benzodiazepines

    Benzodiazepine effects may be potentiated

    Concomitant use not recommended

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords